Source and scope
This summary is bounded to the recommendations, population and decisions covered by Hepatitis C virus: Screening and testing for health professionals. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:PHAC hepatitis C
Source-attributed clinical priorities
- Offer screening for current or past exposure risk and use a reflex pathway from antibody to RNA testing.
- A positive antibody alone does not establish current infection; document confirmatory RNA and assess liver disease and coinfection.
- Link confirmed infection to direct-acting antiviral care and harm-reduction services, with provincial drug-access criteria checked.
- A reactive antibody shows exposure; active infection requires confirmatory RNA testing.
sources for this section:PHAC hepatitis C
Practical assessment and management workflow
1
Assess birth or origin risk, injection equipment, transfusion history, incarceration, tattoos and sexual or household exposures.
2
Use reflex antibody-to-RNA testing where available and assess liver enzymes, platelets and fibrosis.
3
Link RNA-positive patients directly to curative-treatment assessment and vaccination for preventable hepatitis.
4
Confirm treatment response and arrange ongoing liver surveillance only when residual fibrosis risk warrants it.
sources for this section:PHAC hepatitis C
Safety, red flags and urgent escalation
- Jaundice, coagulopathy, encephalopathy or major bleeding suggests decompensated liver disease.
- Review drug interactions and pregnancy before direct-acting antiviral treatment.
- Do not require abstinence from substance use as a blanket condition for hepatitis C care.
sources for this section:PHAC hepatitis C
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:PHAC hepatitis C
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:PHAC hepatitis C
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Public Health Agency of CanadaHepatitis C virus: Screening and testing for health professionalsaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.